Clinical trials: Liver Tumour
Precision Cells, Transcatheter Arterial Chemoembolization
Precision Cell Immunotherapy Combined With TACE in Advanced Liver Cancer
Objectives: To evaluate the safety and effectiveness of cell therapy using Precision Cells Combined With TACE in Advanced Liver Cancer.
- Conditions
- Precision Cells, Transcatheter Arterial Chemoembolization, Advanced Liver Cancer
- Trial name
- NCT02862613
- Testing
- TACE, Precision Cells
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai International Medical Center
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy used to kill tumor cells.
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Liver Cancer
- Trial name
- NCT00007813
- Testing
- filgrastim, carboplatin, cyclophosphamide
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
HCC, Liver Cancer
A Study to Assess the Effect of Y-90 Therapy on Non-target/Background Liver
The primary question of interest is quantifying the relationship between Y-90 liver therapy and liver damage. Little is known on this subject.
- Trial name
- NCT02966223
- Testing
- MRI and HIDA scan
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Indiana University
Hepatocellular Carcinoma
Trial of TRC105 and Sorafenib in Patients With HCC
The purpose of the phase 1b portion is to evaluate safety and tolerability and determine a recommended phase 2 dose for TRC105 when added to standard dose sorafenib in patients with hepatocellular carcinoma.
- Trial name
- NCT02560779
- Testing
- Carotuximab (TRC105), Sorafenib
- Where
- 3 sites in United States
- Volunteers
- 27 people
- Sponsor
- Tracon Pharmaceuticals Inc.
B Cell Lymphoma, B Cell Leukemia
Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors
A single arm, open-label pilot study is designed to determine the safety, efficacy and cytokinetics of CAR T cells in patients with malignant tumors with positive antigen targets.
- Conditions
- B Cell Lymphoma, B Cell Leukemia, Myeloma, Hepatocellular Carcinoma
- Trial name
- NCT03302403
- Testing
- CAR-CD19 T cell, CAR-BCMA T cell, CAR-GPC3 T cell
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Kang YU
Advanced Bile Duct Carcinoma, Stage II Esophageal Cancer AJCC v7
Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation Therapy
This phase I trial studies the side effects and best dose of ropidoxuridine in treating patients with gastrointestinal cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment…
- Conditions
- Advanced Bile Duct Carcinoma, Stage II Esophageal Cancer AJCC v7, Stage II Pancreatic Cancer AJCC v6 and v7, Stage IIA Esophageal Cancer AJCC v7
- Trial name
- NCT02381561
- Testing
- Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Colorectal Carcinoma
A Dose Escalation Study of APR003 in Patients With Advanced Colorectal Cancer (CRC) With Malignant Liver Lesions
A Phase 1 dose escalation study to evaluate APR003 in patients with advanced colorectal cancer (CRC) with malignant liver lesions
- Trial name
- NCT04645797
- Testing
- APR003
- Where
- 4 sites in United States
- Volunteers
- 11 people
- Sponsor
- Apros Therapeutics, Inc
Hepatocellular Carcinoma
Impacts of the α-fetoprotein (AFP) Score in Real Life for Patient Selection for Liver Transplantation (LT) for Hepatocellular Carcinoma (HCC)
This is a French multicentric retrospective study on intention-to-treat comparing results of LT for HCC before and after the use of the AFP score.
- Trial name
- Impact AFP (NCT03156582)
- Testing
- Data collecting
- Where
- France
- Volunteers
- 562 people
- Sponsor
- University Hospital, Grenoble
Pancreatic Neoplasms, Cholangiocarcinoma
Study of Gemcitabine With TheraSphere® (Yttrium-90)in Patients With Hepatic Tumors of Pancreatobiliary Origin
Therasphere is a form of treatment that has been designed to selectively deliver radiation to the cancer within the patient's liver.
- Trial name
- NCT01434459
- Testing
- Gemcitabine with TheraSphere
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Emory University
Colorectal Cancer Metastatic
A Clinical Study of T3011 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer
This is a phase I, open-label clinical study of T3011 in combination with Toraplizumab and Regorafenib in patients with liver metastases from colorectal cancer.
- Trial name
- NCT06283303
- Testing
- T3011 hepatic artery infusion, toripalimab, regorafenib
- Volunteers
- 8 people
- Sponsor
- China Medical University, China
Hepatocellular Carcinoma
A Prospective Study on the Application of Liquid Biopsy in the Surveillance of High-risk Population of HCC.
Liquid biopsy technology based on high-throughput sequencing can detect trace signals in the early stage of cancer in plasma free DNA, so it has become a new technology suitable for tumor diagnosis and screening.Relying on the…
- Trial name
- NCT06134973
- Testing
- ultrasonic testing
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Tianjin Third Central Hospital
Hepatocellular Carcinoma (HCC)
A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)
This Phase 3 study was a global, multicenter trial that randomly assigned participants to either tislelizumab or sorafenib as a first-line treatment for adults with advanced liver cancer (hepatocellular carcinoma) that could not…
- Trial name
- NCT03412773
- Testing
- Tislelizumab, Sorafenib
- Where
- 122 sites in United States, China and 9 more
- Volunteers
- 684 people
- Sponsor
- BeiGene
Hepatocellular Carcinoma, Adult
RCT of TAE Simultaneously Combined Thermal Ablation for Large Hepatocellular Carcinoma
This study intends to evaluate the efficacy and safety of Transarterial embolization (TAE) simultaneously combined with thermal ablation for large hepatocellular carcinoma (HCC).
- Trial name
- NCT02964260
- Testing
- Chemotherapy drug, Embolic agents, Simultaneously
- Where
- China
- Volunteers
- 410 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma (HCC)
Correlation Between Sorafenib Plasma Concentrations, Toxicity and Disease Control Rate in Patients Treated by Sorafenib for Hepatocellular Carcinoma
The aim of this pilot study is to correlate the sorafenib plasma concentration to observed toxicity and to the disease control rate in 100 patients undergoing a palliative treatment of hepatocellular carcinoma (HCC).
- Trial name
- ACTES (NCT02834546)
- Testing
- Sorafenib plasma concentration 4 weeks after treatment initiation
- Where
- 5 sites in France
- Volunteers
- 143 people
- Sponsor
- University Hospital, Bordeaux
Carcinoma, Hepatocellular, Liver Metastases
Study to Evaluate VORTX Rx (Theresa)
Multi-center, Open-labeled, Non-randomized Study to Evaluate the Acute Technical Performance and Safety Profile of the VORTX Rx® for Ablation of Primary and Metastatic Liver Tumors
- Trial name
- Theresa (NCT03741088)
- Testing
- VORTX Rx treatment
- Where
- 3 sites in Spain
- Volunteers
- 8 people
- Sponsor
- HistoSonics, Inc.
Cirrhosis, Hepatocellular Carcinoma
Comparison of Biannual Ultrasonography and Annual Unenhanced Magnetic Resonance Imaging for HCC Surveillance
The purpose of this study is to investigate clinical feasibility of annual non-contrast magnetic resonance imaging for surveillance of hepatocellular carcinoma in high-risk group, in comparison with biannual ultrasonography.
- Trial name
- NCT02854241
- Testing
- Biannual ultrasonography, Annual noncontrast liver MRI, Contrast enhanced liver CT
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- Seoul National University Hospital
Hepatocellular Carcinoma
SHR-1210 Plus Apatinib in Patients With Hepatocellular Carcinoma After Surgery
SHR-1210 is a humanized anti-PD1 Immunoglobulin G4 (IgG4) monoclonal antibody. This is an open- label，single center ，non-randomized ，Single Arm Exploratory Study .
- Trial name
- NCT03722875
- Testing
- SHR-1210, apatinib
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Shanghai Zhongshan Hospital
Liver Cancer
Chemotherapy in Treating Children With Liver Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which chemotherapy regimen is more effective in treating children with liver cancer.
- Trial name
- NCT00003912
- Testing
- carboplatin, cisplatin, doxorubicin hydrochloride
- Where
- Italy
- Volunteers
- 260 people
- Sponsor
- Societe Internationale d'Oncologie Pediatrique
Colorectal Neoplasms, Liver Neoplasms
A Study of Yttrium-90 Radioactive Resin Microspheres to Treat Colorectal Adenocarcinoma Metastatic to the Liver
The purpose of this study is to determine the effectiveness of radioactive microsphere infusion as a treatment for liver metastases from colon or rectal cancer.
- Trial name
- NCT01098422
- Testing
- Yttrium-90 Radioactive Resin Microspheres
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Tony Reid, M.D., Ph.D.
Early Hepatocellular Carcinoma
A Study of Standard Of Care Versus Radio Ablation in Early Stage HCC
This Phase II Prospective, parallel and open-label randomised control trial will investigate whether a radiotherapy technique (called SABR) can treat early stage liver cancer more effectively than current treatments which use…
- Trial name
- SOCRATES HCC (NCT07628751)
- Testing
- Stereotactic Ablative Body Radiotherapy (SABR), Therapies
- Where
- 2 sites in Australia, Canada
- Volunteers
- 218 people
- Sponsor
- University Health Network, Toronto
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.